Cargando…
Isolation and characterization of pharmaceutical grade human pentraxins, serum amyloid P component and C‐reactive protein, for clinical use
The human pentraxin proteins, serum amyloid P component (SAP) and C‐reactive protein (CRP) are important in routine clinical diagnosis, SAP for systemic amyloidosis and CRP for monitoring the non‐specific acute phase response. They are also targets for novel therapies currently in development but th...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4068106/ https://www.ncbi.nlm.nih.gov/pubmed/22867744 http://dx.doi.org/10.1016/j.jim.2012.07.013 |
_version_ | 1782322385667489792 |
---|---|
author | Pepys, Mark B. Gallimore, J. Ruth Lloyd, Joanne Li, Zhanhong Graham, David Taylor, Graham W. Ellmerich, Stephan Mangione, Palma P. Tennent, Glenys A. Hutchinson, Winston L. Millar, David J. Bennett, Gary More, John Evans, David Mistry, Yogesh Poole, Stephen Hawkins, Philip N. |
author_facet | Pepys, Mark B. Gallimore, J. Ruth Lloyd, Joanne Li, Zhanhong Graham, David Taylor, Graham W. Ellmerich, Stephan Mangione, Palma P. Tennent, Glenys A. Hutchinson, Winston L. Millar, David J. Bennett, Gary More, John Evans, David Mistry, Yogesh Poole, Stephen Hawkins, Philip N. |
author_sort | Pepys, Mark B. |
collection | PubMed |
description | The human pentraxin proteins, serum amyloid P component (SAP) and C‐reactive protein (CRP) are important in routine clinical diagnosis, SAP for systemic amyloidosis and CRP for monitoring the non‐specific acute phase response. They are also targets for novel therapies currently in development but their roles in health and disease are controversial. Thus, both for clinical use and to rigorously elucidate their functions, structurally and functionally intact, pharmaceutical grade preparations of the natural, authentic proteins are required. We report here the production from normal human donor plasma and the characterization of the first such preparations. Importantly, we demonstrate that, contrary to reports using recombinant proteins and less well characterized preparations, neither CRP nor SAP stimulate the release by human peripheral blood mononuclear cells in vitro of any TNFα, IL‐6 or IL‐8, nor does SAP cause release of IL‐1β or IL‐10. Furthermore neither of our preparations was pro‐inflammatory in mice in vivo. |
format | Online Article Text |
id | pubmed-4068106 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-40681062014-06-25 Isolation and characterization of pharmaceutical grade human pentraxins, serum amyloid P component and C‐reactive protein, for clinical use Pepys, Mark B. Gallimore, J. Ruth Lloyd, Joanne Li, Zhanhong Graham, David Taylor, Graham W. Ellmerich, Stephan Mangione, Palma P. Tennent, Glenys A. Hutchinson, Winston L. Millar, David J. Bennett, Gary More, John Evans, David Mistry, Yogesh Poole, Stephen Hawkins, Philip N. J Immunol Methods Research Paper The human pentraxin proteins, serum amyloid P component (SAP) and C‐reactive protein (CRP) are important in routine clinical diagnosis, SAP for systemic amyloidosis and CRP for monitoring the non‐specific acute phase response. They are also targets for novel therapies currently in development but their roles in health and disease are controversial. Thus, both for clinical use and to rigorously elucidate their functions, structurally and functionally intact, pharmaceutical grade preparations of the natural, authentic proteins are required. We report here the production from normal human donor plasma and the characterization of the first such preparations. Importantly, we demonstrate that, contrary to reports using recombinant proteins and less well characterized preparations, neither CRP nor SAP stimulate the release by human peripheral blood mononuclear cells in vitro of any TNFα, IL‐6 or IL‐8, nor does SAP cause release of IL‐1β or IL‐10. Furthermore neither of our preparations was pro‐inflammatory in mice in vivo. Elsevier 2012-10-31 /pmc/articles/PMC4068106/ /pubmed/22867744 http://dx.doi.org/10.1016/j.jim.2012.07.013 Text en © 2012 Elsevier B.V. https://creativecommons.org/licenses/by/3.0/ Open Access under CC BY 3.0 (https://creativecommons.org/licenses/by/3.0/) license |
spellingShingle | Research Paper Pepys, Mark B. Gallimore, J. Ruth Lloyd, Joanne Li, Zhanhong Graham, David Taylor, Graham W. Ellmerich, Stephan Mangione, Palma P. Tennent, Glenys A. Hutchinson, Winston L. Millar, David J. Bennett, Gary More, John Evans, David Mistry, Yogesh Poole, Stephen Hawkins, Philip N. Isolation and characterization of pharmaceutical grade human pentraxins, serum amyloid P component and C‐reactive protein, for clinical use |
title | Isolation and characterization of pharmaceutical grade human pentraxins, serum
amyloid P component and C‐reactive protein, for clinical use |
title_full | Isolation and characterization of pharmaceutical grade human pentraxins, serum
amyloid P component and C‐reactive protein, for clinical use |
title_fullStr | Isolation and characterization of pharmaceutical grade human pentraxins, serum
amyloid P component and C‐reactive protein, for clinical use |
title_full_unstemmed | Isolation and characterization of pharmaceutical grade human pentraxins, serum
amyloid P component and C‐reactive protein, for clinical use |
title_short | Isolation and characterization of pharmaceutical grade human pentraxins, serum
amyloid P component and C‐reactive protein, for clinical use |
title_sort | isolation and characterization of pharmaceutical grade human pentraxins, serum
amyloid p component and c‐reactive protein, for clinical use |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4068106/ https://www.ncbi.nlm.nih.gov/pubmed/22867744 http://dx.doi.org/10.1016/j.jim.2012.07.013 |
work_keys_str_mv | AT pepysmarkb isolationandcharacterizationofpharmaceuticalgradehumanpentraxinsserumamyloidpcomponentandcreactiveproteinforclinicaluse AT gallimorejruth isolationandcharacterizationofpharmaceuticalgradehumanpentraxinsserumamyloidpcomponentandcreactiveproteinforclinicaluse AT lloydjoanne isolationandcharacterizationofpharmaceuticalgradehumanpentraxinsserumamyloidpcomponentandcreactiveproteinforclinicaluse AT lizhanhong isolationandcharacterizationofpharmaceuticalgradehumanpentraxinsserumamyloidpcomponentandcreactiveproteinforclinicaluse AT grahamdavid isolationandcharacterizationofpharmaceuticalgradehumanpentraxinsserumamyloidpcomponentandcreactiveproteinforclinicaluse AT taylorgrahamw isolationandcharacterizationofpharmaceuticalgradehumanpentraxinsserumamyloidpcomponentandcreactiveproteinforclinicaluse AT ellmerichstephan isolationandcharacterizationofpharmaceuticalgradehumanpentraxinsserumamyloidpcomponentandcreactiveproteinforclinicaluse AT mangionepalmap isolationandcharacterizationofpharmaceuticalgradehumanpentraxinsserumamyloidpcomponentandcreactiveproteinforclinicaluse AT tennentglenysa isolationandcharacterizationofpharmaceuticalgradehumanpentraxinsserumamyloidpcomponentandcreactiveproteinforclinicaluse AT hutchinsonwinstonl isolationandcharacterizationofpharmaceuticalgradehumanpentraxinsserumamyloidpcomponentandcreactiveproteinforclinicaluse AT millardavidj isolationandcharacterizationofpharmaceuticalgradehumanpentraxinsserumamyloidpcomponentandcreactiveproteinforclinicaluse AT bennettgary isolationandcharacterizationofpharmaceuticalgradehumanpentraxinsserumamyloidpcomponentandcreactiveproteinforclinicaluse AT morejohn isolationandcharacterizationofpharmaceuticalgradehumanpentraxinsserumamyloidpcomponentandcreactiveproteinforclinicaluse AT evansdavid isolationandcharacterizationofpharmaceuticalgradehumanpentraxinsserumamyloidpcomponentandcreactiveproteinforclinicaluse AT mistryyogesh isolationandcharacterizationofpharmaceuticalgradehumanpentraxinsserumamyloidpcomponentandcreactiveproteinforclinicaluse AT poolestephen isolationandcharacterizationofpharmaceuticalgradehumanpentraxinsserumamyloidpcomponentandcreactiveproteinforclinicaluse AT hawkinsphilipn isolationandcharacterizationofpharmaceuticalgradehumanpentraxinsserumamyloidpcomponentandcreactiveproteinforclinicaluse |